EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Combining Reversible Electroporation and Bleomycin in Treatment of Arteriovenous Malformations

Florian Obereisenbuchner, Vanessa F Schmidt, Constantin Goldann, Richard Brill, Daniel Puhr-Westerheide, Elena Borisch, Julia Haehl, Alexandra Hartel, Beate Häberle, Jens Ricke, Max Seidensticker, Melanie A Kimm und 2 weitere

CardioVascular and Interventional Radiology · 2025

DOI: 10.1007/s00270-025-04178-5 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift CardioVascular and Interventional Radiology, 2025. Verfasst von Florian Obereisenbuchner und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, LMU University Hospital, LMU Munich, Munich, Germany. Hauptthemen laut MEDLINE: Bleomycin, Arteriovenous Malformations, Electroporation, Antibiotics, Antineoplastic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Klinikum der Universität München.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This study aims to evaluate and compare safety and clinical outcomes of reversible electroporation with either intravenous (BEST) or intraarterial (BEET) Bleomycin application treating extracranial AVMs unsuitable for conventional approaches defined as fine-fistulous AVMs close to vulnerable anatomical structures (such as skin/end-arteries) not amenable for embolization or resection due to inappropriate risk/benefit and/or therapy-refractory or recurrent lesions. Materials and Methods This is a sub-analysis of the prospective multicenter APOLLON trial (German clinical trial register, DRKS00021019). Clinical and imaging findings were assessed at baseline and 6-month follow-up to evaluate subjective outcome (symptom-free, partial relief, no improvement, clinical progression) and AVM lesion devascularization on MRI (total, 100%; substantial, 76–99%; partial, 51–75%; slight, 50%; progression). BEST versus BEET was at the discretion of the operator; subgroup outcome comparisons were subsequently performed.

Results

Twenty-one AVM patients received 31 treatments (16/31 BEST, 51.6%; 15/31 BEET, 48.4%); the mean number of procedures per patient was 1.5 (± 0.7). Complications occurred after 7/31 (22.6%) procedures, including 6.4% major complications (delayed wound healing solved by split-skin transplantation, persistant scarring). Subjective outcome revealed partial symptom relief in 13/21 (61.9%) patients, and 4/21 (19.0%) patients presented symptom-free. In 4/21 (19.0%) patients, no improvement or symptom worsening was reported. Imaging revealed complete devascularization in one case (6.3%), substantial (76–99%) and partial (51–75%) devascularization in 6/16 (36.5%) patients, respectively, while progression was noted in 3/16 (18.8%) patients. Comparison of clinical outcomes differed between both approaches, with BEET being superior to BEST ( p = 0.04).

Conclusion

The combination of reversible electroporation and bleomycin is effective for treatment of AVMs; BEET tends to present superior to BEST regarding patients ’ outcome.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BleomycinArteriovenous MalformationsElectroporationAntibiotics, AntineoplasticHumansMaleFemaleAdultProspective StudiesTreatment OutcomeMiddle AgedAdolescentCombined Modality TherapyMagnetic Resonance ImagingYoung Adult

Stichwörter der Autor:innen

AVMBEETBESTBleomycinBleomycin electroembolotherapyBleomycin electrosclerotherapy

Substanzen

BleomycinAntibiotics, Antineoplastic

Autor:innen und Institutionen

  • Department of Radiology, LMU University Hospital, LMU Munich, Munich, Germany.
  • Interdisciplinary Center for Vascular Anomalies (IZGA), LMU University Hospital, LMU Munich, Munich, Germany.
  • Department of Radiology, LMU University Hospital, LMU Munich, Munich, Germany. Vanessa.Schmidt@med.uni-muenchen.de.
  • Interdisciplinary Center for Vascular Anomalies (IZGA), LMU University Hospital, LMU Munich, Munich, Germany. Vanessa.Schmidt@med.uni-muenchen.de.
  • Clinic and Policlinic of Radiology, Martin-Luther University Halle-Wittenberg, Halle (Saale), Germany.
  • Department of Diagnostic and Interventional Radiology and Neuroradiology, München Klinik Harlaching, Munich, Germany.

Förderung

  • Klinikum der Universität München

Zitieren

APA

Obereisenbuchner, F., Schmidt, V. F., Goldann, C., Brill, R., Puhr-Westerheide, D., Borisch, E., Haehl, J., Hartel, A., Häberle, B., Ricke, J., Seidensticker, M., Kimm, M. A., Wildgruber, M., & Wohlgemuth, W. A. (2025). Combining Reversible Electroporation and Bleomycin in Treatment of Arteriovenous Malformations. CardioVascular and Interventional Radiology. https://doi.org/10.1007/s00270-025-04178-5

Vancouver

Obereisenbuchner F, Schmidt VF, Goldann C, Brill R, Puhr-Westerheide D, Borisch E, et al. Combining Reversible Electroporation and Bleomycin in Treatment of Arteriovenous Malformations. CardioVascular and Interventional Radiology. 2025. doi:10.1007/s00270-025-04178-5

BibTeX
@article{Obereisenbuchner2025,
  author = {Obereisenbuchner, Florian and Schmidt, Vanessa F and Goldann, Constantin and Brill, Richard and Puhr-Westerheide, Daniel and Borisch, Elena and Haehl, Julia and Hartel, Alexandra and Häberle, Beate and Ricke, Jens and Seidensticker, Max and Kimm, Melanie A and Wildgruber, Moritz and Wohlgemuth, Walter A},
  title = {Combining Reversible Electroporation and Bleomycin in Treatment of Arteriovenous Malformations},
  journal = {CardioVascular and Interventional Radiology},
  year = {2025},
  doi = {10.1007/s00270-025-04178-5}
}
Kostenlos starten →